How should Hurler syndrome be diagnosed and managed, particularly in children under two years with the severe phenotype?

Hurler Syndrome: Diagnosis and Management

For children under two years with severe Hurler syndrome (MPS I-H), hematopoietic stem cell transplantation (HSCT) performed before 24 months of age—ideally before 9 months—is the definitive treatment to preserve neurocognitive function and prolong survival, with enzyme replacement therapy (ERT) used as a bridge or adjunct based on clinical judgment. 1

Diagnostic Approach

Initial Confirmation

• Confirm diagnosis with leukocyte α-L-iduronidase enzyme activity testing following positive newborn screening or clinical suspicion 1
• Proceed to IDUA gene sequencing when enzyme activity is low to determine genotype and predict phenotype severity 1
• Refer immediately to a metabolic center for comprehensive evaluation and genetic counseling 1

Baseline Multidisciplinary Evaluation

All confirmed MPS I-H patients require systematic assessment including 1:

• Ophthalmology: Assess for corneal clouding
• Otolaryngology and audiometry: Evaluate hearing (98% show failed newborn hearing screen) 2
• Cardiology with echocardiography and ECG: Detect early valvular disease
• Orthopedic surgery: Identify dysostosis multiplex on plain radiography (J-shaped sella turcica, spatulate ribs, wedge-shaped vertebral bodies, proximal pointing of metacarpals, coxa valga) 1
• Pulmonology and polysomnography: Assess airway obstruction and respiratory symptoms (common in first 6 months) 2
• Neurodevelopmental assessment: Establish baseline cognitive function (developmental quotient)
• Pediatric neurosurgery: Evaluate for hydrocephalus risk
• Brain and spine MRI: Document baseline CNS involvement
• Abdominal ultrasound: Assess organomegaly

Critical timing note: 98% of Hurler patients show disease signs within the first 6 months of life, including respiratory symptoms, feeding difficulties, otitis media, kyphosis, and enlarged head circumference appearing by 8-10 months 2

Management Algorithm for Severe Phenotype (MPS I-H)

Immediate Actions Upon Diagnosis

1. Initiate HSCT evaluation immediately with hematology/oncology referral 1
2. Arrange surgical consultation for central venous catheter placement 1
3. Consider ERT initiation based on clinical judgment of the metabolic specialist, particularly if significant cardiopulmonary disease is present 1
   • Some centers avoid pre-HSCT ERT due to concern for anti-iduronidase antibodies interfering with engraftment, while others report reduced pulmonary complications with combined therapy 1
4. Establish neurodevelopmental monitoring every 3-4 months to track developmental trajectory 1

Optimal Timing for HSCT

HSCT must be performed before 24 months of age and before onset of significant developmental delay to achieve the highest probability of rescuing neurocognitive outcomes 1. The evidence is compelling:

• Children transplanted before 9 months show normal cognitive development 3
• Younger age at transplantation strongly predicts better cognitive function, receptive/expressive language, and adaptive behavior (p = 0.001 for cognition) 3
• Survival and engraftment rates have improved to 85-90% in recent series 1
• Stem cells from donors without IDUA mutations correlate with higher post-transplant enzyme activity, better GAG clearance, and superior developmental outcomes compared to heterozygous donors 1

ERT Monotherapy Is Insufficient for Severe Disease

ERT alone does not adequately treat the neurodegenerative component of Hurler syndrome due to blood-brain barrier impermeability 4. A multicenter comparison demonstrated:

• Worse survival with ERT monotherapy versus HSCT 4
• Higher cumulative incidence of hydrocephalus and cervical spinal cord compression with ERT versus HSCT 4
• ERT cannot prevent CNS deterioration, supporting current guidelines to treat severe phenotype with HSCT 4

Emerging Gene Therapy Option

Autologous hematopoietic stem and progenitor cell gene therapy (HSPC-GT) shows promising results in recent trials 5, 6, 7:

• Supraphysiologic IDUA activity achieved within one month and maintained long-term 5
• Superior metabolic correction compared to allo-HSCT with GAG normalization in cerebrospinal fluid 5
• Stable cognitive performance and motor development with improved skeletal outcomes including normalized joint mobility and growth within WHO reference ranges 7
• Favorable safety profile without graft failure or insertional oncogenesis up to 4 years follow-up 6
• Currently available through clinical trials for patients lacking suitable allogeneic donors 5

Management of Uncertain Phenotype

For patients with novel IDUA mutations or variants like p.P533R (which encompasses the entire MPS I spectrum) 1:

1. Monitor regularly with metabolic physician and subspecialists every 3 months 1
2. Evaluate for potential HSCT and identify donor, placing patient "on hold" for transplantation 1
3. Perform neurodevelopmental assessments every 3-4 months 1
4. Proceed with HSCT if markers of severe disease emerge: developmental delay, severe organomegaly, progressive skeletal manifestations 1

Critical caveat: Enzyme activity levels are unreliable for phenotypic prediction, making genotype-phenotype correlation the primary decision-making tool despite its limitations 1

Long-Term Monitoring Post-HSCT

Even after successful HSCT, patients require ongoing surveillance 1, 8:

• Neurodevelopmental follow-up: Expect potential speech delay and learning disabilities; cognitive function may show initial delays followed by normalization 1-2 years post-transplant 1, 8
• Orthopedic monitoring: Spine and hip operations, carpal tunnel syndrome may still be required 8
• Cardiac surveillance: Valve involvement can remain progressive despite HSCT 8
• Audiometry and polysomnography: Periodic assessment for hearing loss and airway obstruction 1
• Skeletal imaging: Monitor for craniovertebral junction abnormalities, though only 7.4% require surgical intervention 9

Final height typically reaches 1-3 standard deviations below the mean despite treatment 1